Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Medical experts outline the current first-line treatment options for advanced non–clear cell RCC, including the factors influencing agent selection, as well as discuss how recent NCCN guideline updates and label changes affect treatment decisions in community practice.
EP: 1.Overview of RCC: Clear-Cell and Non–clear Cell
EP: 2.Challenges in Treating RCC From Community and Academic Settings
EP: 3.Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
EP: 4.KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice
EP: 5.nccRCC: Alternative Therapies
EP: 6.Role of Histology and Data in Selecting Optimal Therapy in nccRCC
EP: 7.AE Management of IO/TKI and Future of nccRCC
EP: 8.KEYNOTE-564: Pembrolizumab as Adjuvant Therapy
EP: 9.NCCN Guideline Updates in Clear-Cell RCC
EP: 10.Best Treatment Selection in Clear-Cell RCC
Video content above is prompted by the following:
Describe the current available first-line treatment options for advanced nccRCC.
- What patient, disease, and/or other characteristics do you consider when selecting a first-line agent?
- How do the NCCN guideline updates or specific label updates/changes impact your decision makingdecision-making when choosing a preferred regimen?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
